
Indivior PLC (INDV) Stock Forecast & Price Target
Indivior PLC (INDV) Analyst Ratings
Bulls say
Indivior PLC reported a substantial growth in its Sublocade treatment, with approximately 171,500 patients in 3Q25, reflecting an 8% increase compared to 3Q24, and an increase in prescribers by 11%. The company has raised its worldwide sales guidance for Sublocade to approximately $825M-$845M, indicating a robust annual growth rate of around 10% at the midpoint. Additionally, the overall sales for Indivior grew by approximately 14% in 3Q25 versus the same quarter in the previous year, positioning the company favorably amid increasing public awareness and acceptance of medication-assisted treatments (MATs).
Bears say
Indivior PLC faces a challenging outlook primarily due to the anticipated decline in revenue from Suboxone, driven by generic competition, which threatens to erode a significant portion of its income. Although there is potential for growth from Sublocade, it is still early in its commercial lifecycle, raising concerns about its ability to fully offset the revenue loss from Suboxone. Additionally, projected high levels of selling, general, and administrative (SG&A) expenses, estimated to be around 45% of revenue in 2026, may further strain the company's profitability amidst these revenue pressures.
This aggregate rating is based on analysts' research of Indivior PLC and is not a guaranteed prediction by Public.com or investment advice.
Indivior PLC (INDV) Analyst Forecast & Price Prediction
Start investing in Indivior PLC (INDV)
Order type
Buy in
Order amount
Est. shares
0 shares